SCHEDULE: Armistice Capital Discloses 11.43% Stake in Aridis Pharmaceuticals

Armistice Capital, LLC and Steven Boyd have reported a beneficial ownership of 11.43% in Aridis Pharmaceuticals, Inc. common stock as of March 31, 2026.

Summary

• Armistice Capital, LLC, through its investment manager role, and Steven Boyd, as the managing member of Armistice Capital, have collectively reported beneficial ownership of 5,096,251 shares of Aridis Pharmaceuticals, Inc. common stock.
• This holding represents 11.43% of the total class of securities.
• The shares are directly held by Armistice Capital Master Fund Ltd., an investment advisory client of Armistice Capital.
• Armistice Capital exercises voting and investment power over the securities held by the Master Fund.
• The Master Fund disclaims beneficial ownership due to its investment management agreement with Armistice Capital.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing neutrally as it is a standard disclosure of beneficial ownership and does not provide new operational or financial information about the company itself.

Positives

• Significant ownership stake (11.43%) in Aridis Pharmaceuticals, Inc. by a known investment entity.
• Clear disclosure of beneficial ownership, indicating active investment management.

Negatives

• The Master Fund disclaims beneficial ownership of the shares it directly holds, which could indicate a complex ownership structure or specific regulatory considerations.
• No specific financial performance or strategic updates are provided in this filing, as it is a Schedule 13G focused on ownership.

Risks

• Potential for future changes in ownership stake, which could impact share price.
• The nature of the investment management agreement and the disclaimer of beneficial ownership by the Master Fund could introduce complexities or potential future disputes.
• Concentration of ownership by a single entity could lead to increased volatility if that entity decides to divest.

Future Outlook

This filing is a Schedule 13G, which primarily reports beneficial ownership and does not contain forward-looking statements or financial guidance from the company.

Management Comments

• Armistice Capital, LLC is the investment manager of Armistice Capital Master Fund Ltd., the direct holder of the Shares, and pursuant to an Investment Management Agreement, Armistice Capital exercises voting and investment power over the securities of the Issuer held by the Master Fund and thus may be deemed to beneficially own the securities of the Issuer held by the Master Fund.
• Mr. Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the securities of the Issuer held by the Master Fund.
• The Master Fund specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital.

Industry Context

StockSavvy.ai notes that significant ownership disclosures via Schedule 13G filings often precede or coincide with activist investor campaigns or strategic shifts within a company. This filing indicates a substantial position taken by Armistice Capital in Aridis Pharmaceuticals, a biotechnology company, suggesting a potential interest in the company's strategic direction or valuation.

Stakeholder Impact

• Shareholders: May see increased volatility or potential for activist engagement due to the significant stake held by Armistice Capital.
• Management of Aridis Pharmaceuticals: May face increased scrutiny or engagement from Armistice Capital regarding company strategy and performance.
• Potential Investors: This disclosure may attract attention from other investors interested in Aridis Pharmaceuticals, potentially influencing trading activity.

Next Steps

• Monitor future filings from Armistice Capital and Aridis Pharmaceuticals for any changes in ownership or strategic announcements.
• Observe Aridis Pharmaceuticals' performance and strategic initiatives to understand the context of Armistice Capital's investment.

Key Dates

Recommendation

This filing is a Schedule 13G, which reports a significant ownership stake but does not provide new operational or financial performance data for Aridis Pharmaceuticals. Therefore, a 'hold' recommendation is appropriate, pending further information on the company's performance and Armistice Capital's intentions.

Keywords

Aridis Pharmaceuticals, Armistice Capital, Schedule 13G, Beneficial Ownership, Common Stock, Investment Management, SEC Filing, Shareholder